Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab versus teriflunomide in adults with relapsing multiple sclerosis
NL-OMON59342Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of frexalimab in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Annualized relapse rate during the study period. Started Feb 2024; status: completed.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON59342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59342.